{"id":50222,"date":"2022-10-28T16:01:55","date_gmt":"2022-10-28T14:01:55","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/exscientia-wins-prix-galien-usa-2022-digital-health-solution-award\/"},"modified":"2022-10-28T16:01:55","modified_gmt":"2022-10-28T14:01:55","slug":"exscientia-wins-prix-galien-usa-2022-digital-health-solution-award","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/exscientia-wins-prix-galien-usa-2022-digital-health-solution-award\/","title":{"rendered":"Exscientia Wins Prix Galien USA 2022 Digital Health Solution Award"},"content":{"rendered":"
\n

\nBiopharma industry\u2019s coveted prize recognizes company\u2019s AI-driven precision medicine platform<\/i>\n<\/p>\n

OXFORD, England–(BUSINESS WIRE)–Exscientia plc (Nasdaq: EXAI) is honoured to announce that the company has won the Prix Galien USA 2022 Award for Best Digital Health Solution in recognition of its AI-driven precision medicine platform. The award was presented Thursday at the Prix Galien Forum in New York City. Worldwide, the Prix Galien, which recognizes excellence in scientific innovation that improves the state of human health, is regarded as the most coveted prize in biopharmaceutical research.\n<\/p>\n

<\/a><\/p>\n

\nExscientia is focused on designing fundamentally better drugs \u2013 faster. The company\u2019s artificial intelligence (AI)-driven functional precision medicine platform enables a \u201cpatient-first\u201d approach by integrating primary human tissue samples into early target and drug discovery research. Earlier this year, the next-generation platform, which aims to reinvent the way drugs are discovered and developed, was clinically proven to guide treatment selection and improve cancer treatment outcomes, in the landmark EXALT-1 study.\n<\/p>\n

\nEXALT-1 demonstrated the ability of one of Exscientia\u2019s AI-discovered medicines to improve cancer treatment outcomes, <\/i>marking the first time a functional precision oncology platform improved patient outcomes in an interventional clinical study. Today, the live tissue technology used in that study is a core component underpinning Exscientia\u2019s end-to-end platform, which has discovered the first three AI-designed molecules to enter clinical trials, dramatically cutting the time and cost required to generate novel molecules with the potential to become approved medicines.\n<\/p>\n

\n\u201cSincere thanks to the Galien Foundation and Business France for this incredible honour. Exscientia is humbled to receive this recognition and grateful to our incredible team whose vision made it possible,\u201d said Exscientia founder and CEO Andrew Hopkins, DPhil. \u201cThis award is a recognition of the enormous potential that AI holds to transform how our industry discovers and develops the right drug for the right patient. This award recognized the potential of our AI driven precision medicine platform to truly bring the vision of personalised medicine to the benefit of the patient. The day is coming when all medicines will be discovered and developed by harnessing the power of AI. At Exscientia, we are proud to be pioneering the way forward.\u201d\n<\/p>\n

\nAbout Exscientia<\/b>\n<\/p>\n

\nExscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our internal pipeline is focused on leveraging our precision medicine platform in oncology, while our partnered pipeline broadens our approach to other therapeutic areas. By pioneering a new approach to medicine creation, we believe the best ideas of science can rapidly become the best medicines for patients.\n<\/p>\n

\nExscientia is headquartered in Oxford (England, U.K.), with offices in Vienna (Austria), Dundee (Scotland, U.K.), Boston (Mass., U.S.), Miami (Fla., U.S.), Cambridge (England, U.K.), and Osaka (Japan).\n<\/p>\n

\nVisit us at www.exscientia.ai<\/a> or follow us on Twitter @exscientiaAI<\/a>.\n<\/p>\n

\nForward-looking statements<\/b>\n<\/p>\n

\nThis press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to the progress of discovery and development of candidate molecules, and the timing and progress of, and data reported from, clinical trials of Exscientia\u2019s product candidates, and Exscientia\u2019s expectations regarding its projected revenue and cash runway. Any statement describing Exscientia\u2019s goals, plans, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to a number of risks, uncertainties and assumptions, including those related to: the impact that the COVID-19 pandemic could have on the Company\u2019s business, including the scope, progress and expansion of Exscientia\u2019s product development efforts; the initiation, scope and progress of Exscientia\u2019s and its partners\u2019 planned and ongoing pre-clinical studies and clinical trials and ramifications for the cost thereof; clinical, scientific, regulatory and technical developments; the process of discovering, developing and commercialising product candidates that are safe and effective for use as human therapeutics; and the endeavour of building a business around such product candidates. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Exscientia\u2019s Annual Report on Form 20-F, filed with the Securities and Exchange Commission (SEC) on March 23, 2022 (File No. 001-40850), and other filings that Exscientia makes with the SEC from time to time (which are available at https:\/\/www.sec.gov\/<\/a>), the events and circumstances discussed in such forward-looking statements may not occur, and Exscientia\u2019s actual results could differ materially and adversely from those anticipated or implied thereby. Although Exscientia\u2019s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by the Company. As a result, you are cautioned not to rely on these forward-looking statements.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestors:<\/b>
Sara Sherman
\n
investors@exscientia.ai<\/a>\n<\/p>\n

\nMedia:<\/b>
media@exscientia.ai<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Biopharma industry\u2019s coveted prize recognizes company\u2019s AI-driven precision medicine platform OXFORD, England–(BUSINESS WIRE)–Exscientia plc (Nasdaq: EXAI) is honoured to announce that the company has won the Prix Galien USA 2022 Award for Best Digital Health Solution in recognition of its AI-driven precision medicine platform. The award was presented Thursday at the Prix Galien Forum in … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-50222","6":"format-standard","7":"category-industry"},"yoast_head":"\nExscientia Wins Prix Galien USA 2022 Digital Health Solution Award - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/exscientia-wins-prix-galien-usa-2022-digital-health-solution-award\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Exscientia Wins Prix Galien USA 2022 Digital Health Solution Award - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Biopharma industry\u2019s coveted prize recognizes company\u2019s AI-driven precision medicine platform OXFORD, England–(BUSINESS WIRE)–Exscientia plc (Nasdaq: EXAI) is honoured to announce that the company has won the Prix Galien USA 2022 Award for Best Digital Health Solution in recognition of its AI-driven precision medicine platform. The award was presented Thursday at the Prix Galien Forum in ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/exscientia-wins-prix-galien-usa-2022-digital-health-solution-award\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-28T14:01:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221028005290\/en\/1617685\/21\/Exscientia_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-wins-prix-galien-usa-2022-digital-health-solution-award\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-wins-prix-galien-usa-2022-digital-health-solution-award\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Exscientia Wins Prix Galien USA 2022 Digital Health Solution Award\",\"datePublished\":\"2022-10-28T14:01:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-wins-prix-galien-usa-2022-digital-health-solution-award\\\/\"},\"wordCount\":855,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-wins-prix-galien-usa-2022-digital-health-solution-award\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221028005290\\\/en\\\/1617685\\\/21\\\/Exscientia_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-wins-prix-galien-usa-2022-digital-health-solution-award\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-wins-prix-galien-usa-2022-digital-health-solution-award\\\/\",\"name\":\"Exscientia Wins Prix Galien USA 2022 Digital Health Solution Award - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-wins-prix-galien-usa-2022-digital-health-solution-award\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-wins-prix-galien-usa-2022-digital-health-solution-award\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221028005290\\\/en\\\/1617685\\\/21\\\/Exscientia_Logo.jpg\",\"datePublished\":\"2022-10-28T14:01:55+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-wins-prix-galien-usa-2022-digital-health-solution-award\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-wins-prix-galien-usa-2022-digital-health-solution-award\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-wins-prix-galien-usa-2022-digital-health-solution-award\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221028005290\\\/en\\\/1617685\\\/21\\\/Exscientia_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221028005290\\\/en\\\/1617685\\\/21\\\/Exscientia_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-wins-prix-galien-usa-2022-digital-health-solution-award\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Exscientia Wins Prix Galien USA 2022 Digital Health Solution Award\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Exscientia Wins Prix Galien USA 2022 Digital Health Solution Award - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/exscientia-wins-prix-galien-usa-2022-digital-health-solution-award\/","og_locale":"en_US","og_type":"article","og_title":"Exscientia Wins Prix Galien USA 2022 Digital Health Solution Award - Pharma Trend","og_description":"Biopharma industry\u2019s coveted prize recognizes company\u2019s AI-driven precision medicine platform OXFORD, England–(BUSINESS WIRE)–Exscientia plc (Nasdaq: EXAI) is honoured to announce that the company has won the Prix Galien USA 2022 Award for Best Digital Health Solution in recognition of its AI-driven precision medicine platform. The award was presented Thursday at the Prix Galien Forum in ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/exscientia-wins-prix-galien-usa-2022-digital-health-solution-award\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-28T14:01:55+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221028005290\/en\/1617685\/21\/Exscientia_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/exscientia-wins-prix-galien-usa-2022-digital-health-solution-award\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/exscientia-wins-prix-galien-usa-2022-digital-health-solution-award\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Exscientia Wins Prix Galien USA 2022 Digital Health Solution Award","datePublished":"2022-10-28T14:01:55+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/exscientia-wins-prix-galien-usa-2022-digital-health-solution-award\/"},"wordCount":855,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/exscientia-wins-prix-galien-usa-2022-digital-health-solution-award\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221028005290\/en\/1617685\/21\/Exscientia_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/exscientia-wins-prix-galien-usa-2022-digital-health-solution-award\/","url":"https:\/\/pharma-trend.com\/en\/exscientia-wins-prix-galien-usa-2022-digital-health-solution-award\/","name":"Exscientia Wins Prix Galien USA 2022 Digital Health Solution Award - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/exscientia-wins-prix-galien-usa-2022-digital-health-solution-award\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/exscientia-wins-prix-galien-usa-2022-digital-health-solution-award\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221028005290\/en\/1617685\/21\/Exscientia_Logo.jpg","datePublished":"2022-10-28T14:01:55+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/exscientia-wins-prix-galien-usa-2022-digital-health-solution-award\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/exscientia-wins-prix-galien-usa-2022-digital-health-solution-award\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/exscientia-wins-prix-galien-usa-2022-digital-health-solution-award\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221028005290\/en\/1617685\/21\/Exscientia_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221028005290\/en\/1617685\/21\/Exscientia_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/exscientia-wins-prix-galien-usa-2022-digital-health-solution-award\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Exscientia Wins Prix Galien USA 2022 Digital Health Solution Award"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50222","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=50222"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50222\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=50222"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=50222"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=50222"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}